Revenues (Details) $ in Millions	3 Months Ended
	Mar. 31, 2021 USD ($) segment	Mar. 31, 2020 USD ($)
Revenue from Contract with Customer [Abstract]
Number of operating segments | segment	1
Revenue from External Customer [Line Items]
Total revenues	$ 5,901	$ 6,161
Product sales [Member]
Revenue from External Customer [Line Items]
Total product sales	5,592	5,894
Product sales [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales	3,903	4,279
Product sales [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	1,689	1,615
Enbrel® (etanercept) [Member]
Revenue from External Customer [Line Items]
Total product sales	924	1,153
Enbrel® (etanercept) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales	894	1,117
Enbrel® (etanercept) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	30	36
Prolia® (denosumab) [Member]
Revenue from External Customer [Line Items]
Total product sales	758	654
Prolia® (denosumab) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales	501	422
Prolia® (denosumab) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	257	232
Neulasta® (pegfilgrastim) [Member]
Revenue from External Customer [Line Items]
Total product sales	482	609
Neulasta® (pegfilgrastim) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales	421	534
Neulasta® (pegfilgrastim) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	61	75
Otezla (apremilast) [Member]
Revenue from External Customer [Line Items]
Total product sales	476	479
Otezla (apremilast) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales	366	377
Otezla (apremilast) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	110	102
XGEVA® (denosumab) [Member]
Revenue from External Customer [Line Items]
Total product sales	468	481
XGEVA® (denosumab) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales	334	355
XGEVA® (denosumab) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	134	126
Aranesp® (darbepoetin alfa) [Member]
Revenue from External Customer [Line Items]
Total product sales	355	422
Aranesp® (darbepoetin alfa) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales	125	175
Aranesp® (darbepoetin alfa) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	230	247
Repatha (evolocumab) [Member]
Revenue from External Customer [Line Items]
Total product sales	286	229
Repatha (evolocumab) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales	139	124
Repatha (evolocumab) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	147	105
KYPROLIS® (carfilzomib) [Member]
Revenue from External Customer [Line Items]
Total product sales	251	280
KYPROLIS® (carfilzomib) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales	159	187
KYPROLIS® (carfilzomib) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	92	93
Other products [Member]
Revenue from External Customer [Line Items]
Total product sales	1,592	1,587
Other products [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales	964	988
Other products [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	628	599
Other revenues [Member]
Revenue from External Customer [Line Items]
Total revenues	$ 309	$ 267